Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥2,381 JPY
Change Today 0.00 / 0.00%
Volume 161.2K
As of 1:00 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

kyorin holdings inc (4569) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/12/15 - ¥3,040
52 Week Low
09/29/15 - ¥1,782
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KYORIN HOLDINGS INC (4569)

Related News

No related news articles were found.

kyorin holdings inc (4569) Related Businessweek News

No Related Businessweek News Found

kyorin holdings inc (4569) Details

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical, generic, over-the-counter drugs, and others in Japan and internationally. The company operates in two segments, Pharmaceutical Business and Consumer Healthcare (Skincare) Business. Its products primarily include Flutiform, a drug for the treatment of asthma; Uritos, which is a therapeutic agent for overactive bladder; Kipres for the treatment of bronchial asthma and allergic rhinitis; Pentasa for the treatment of ulcerative colitis and Crohn’s disease; and Mucodyne, a mucoregulan drug. The company also offers Milton, a baby bottle disinfectant; Rubysta, a disinfectant cleaner; skincare and cosmetic products based on nanocapsule technology, a pharmaceutical formulation concept; and prescription medicines and quasi-drugs, diagnostics, and industrial chemicals. In addition, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trials. Further, the company’s pipeline products include KRP-AB1102 and KRP-AB1102F for the treatment of chronic obstructive pulmonary disease that are under Phase III clinical development; KRP-AM1977X for the treatment of infectious diseases that is under Phase II clinical development; and KRP-114V and KRP-EPA605 for overactive bladder. Additionally, it pipeline products comprise KRP-209 for Tinnitus; KRP-203 for transplantation, autoimmune diseases, and IBD; KRP-AM1977X, an oral antibacterial agent; and KRP-AM1977Y, an injection. The company’s other pipeline products include Ad-SGE-REIC formulation, a gene-therapy product; and Dimethyl sulfoxide for the treatment of interstitial cystitis. KYORIN Holdings, Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

2,445 Employees
Last Reported Date: 06/24/15
Founded in 1923

kyorin holdings inc (4569) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyorin holdings inc (4569) Key Developments

KYORIN Holdings, Inc. to Report Q2, 2016 Results on Nov 05, 2015

KYORIN Holdings, Inc. announced that they will report Q2, 2016 results on Nov 05, 2015

KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2015; Announces Dividend for the Second Quarter of Fiscal 2016, Payable on December 4, 2015; Revises Dividend for the Year End Ending March 31, 2016; Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2016

KYORIN Holdings, Inc. reported consolidated earnings results for the six months ended September 30, 2015. For the six months, the company reported consolidated net sales of JPY 52,386 million, operating income of JPY 4,099 million, ordinary income of JPY 4,266 million, profit attributable to owners of parent of JPY 2,967 million or JPY 40.10 per diluted share, compared to net sales of JPY 51,112 million, operating income of JPY 4,587 million, ordinary income of JPY 4,898 million, profit attributable to owners of parent of JPY 3,495 million or JPY 46.78 per diluted share, a year ago. The company announced dividend of JPY 20.00 per share for the second quarter of fiscal 2016, compared to JPY 20.00 per share a year ago. The dividend will be payable on December 4, 2015. The company revised dividend guidance of JPY 32.00 per share for the year end ending March 31, 2016, compared to JPY 32.00 per share, a year ago. The company provided consolidated earnings guidance for the full year ending March 31, 2016. For the full year, the company is forecasting its net sales of JPY 120,200 million, operating income of JPY 16,000 million, ordinary income of JPY 16,300 million, profit attributable to owners of parent of JPY 11,500 million or JPY 155.51 per share.

KYORIN Holdings, Inc., Q2 2016 Earnings Call, Nov 06, 2015

KYORIN Holdings, Inc., Q2 2016 Earnings Call, Nov 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4569:JP ¥2,381.00 JPY 0.00

4569 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4569.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4569 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KYORIN HOLDINGS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at